Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance
5 affiliations
- 1Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
- 2Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, 16111 Plummer Street (151), Building 1, Room C111A, Los Angeles, CA 91343, USA
- 3Departments of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
- 4Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA 90024, USA
- 5Molecular Biology Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA
Abstract
Glioblastoma (GBM) is the most common and highly malignant primary brain tumor in adults. Even with advances in surgery, radiotherapy, and systemic therapies, patient outcomes remain poor due to extensive intratumoral heterogeneity and the development of therapeutic resistance. Circular RNAs (circRNAs) are a class of covalently closed RNA molecules that are highly abundant in the central nervous system and frequently dysregulated in cancer. While originally considered non-coding transcripts, current evidence demonstrates that a subset of circRNAs contain functional open reading frames and can undergo cap-independent translation to generate biologically active proteins and peptides. Recent studies have identified a growing number of translated circRNAs in GBM encoding proteins implicated in diverse processes such as receptor tyrosine kinase signaling, DNA repair, metabolism, stemness, invasion, and therapeutic resistance. These findings expand the coding potential of the GBM transcriptome and highlight an additional layer of post-transcriptional regulation. In this review, we summarize our current understanding of circRNA translation, discuss the biological functions of translated circRNAs in GBM, and examine their potential roles in tumor progression, therapeutic resistance, and clinical management. Additionally, we consider the opportunities and challenges associated with targeting translated circRNAs and their encoded proteins for the treatment of GBM.
Related
- Changing Course: Semaphorins and Plexins as Novel Therapeutic Opportunities and Key Regulators of Pancreatic Cancer Microenvironment
- Deubiquitinases as Regulators and Therapeutic Targets in Vascular Diseases
- Anatomical Heterogeneity in Longitudinal CA15-3 and CEA Rises Preceding Metastatic Breast Cancer Progression
- A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity
- Editorial: E3 ubiquitin ligases: critical roles in cancer progression and therapeutic implications
BibTeX
@article{nishimura2026translated,
title = {{Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance}},
author = {Robert N. Nishimura and Joseph F. Gera},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198743},
url = {https://www.mdpi.com/1422-0067/27/19/8743},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance
AU - Robert N. Nishimura
AU - Joseph F. Gera
PY - 2026
DA - 2026/09/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198743
UR - https://www.mdpi.com/1422-0067/27/19/8743
AB - Glioblastoma (GBM) is the most common and highly malignant primary brain tumor in adults. Even with advances in surgery, radiotherapy, and systemic therapies, patient outcomes remain poor due to extensive intratumoral heterogeneity and the development of therapeutic resistance. Circular RNAs (circRNAs) are a class of covalently closed RNA molecules that are highly abundant in the central nervous system and frequently dysregulated in cancer. While originally considered non-coding transcripts, current evidence demonstrates that a subset of circRNAs contain functional open reading frames and can undergo cap-independent translation to generate biologically active proteins and peptides. Recent studies have identified a growing number of translated circRNAs in GBM encoding proteins implicated in diverse processes such as receptor tyrosine kinase signaling, DNA repair, metabolism, stemness, invasion, and therapeutic resistance. These findings expand the coding potential of the GBM transcriptome and highlight an additional layer of post-transcriptional regulation. In this review, we summarize our current understanding of circRNA translation, discuss the biological functions of translated circRNAs in GBM, and examine their potential roles in tumor progression, therapeutic resistance, and clinical management. Additionally, we consider the opportunities and challenges associated with targeting translated circRNAs and their encoded proteins for the treatment of GBM.
SN - 1422-0067
ER -